AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05018676
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mgkg IV infusion on Day 1 of each 21-day treatment cycle.
Trial: NCT04273997
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment
Trial: NCT06653842
Drug: QTORIN 3.9% rapamycin anhydrous gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QTORIN 3.9% Rapamycin Anhydrous Gel
Trial: NCT05312970
Drug: Varithena®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varithena® (polidocanol injectable foam) 1%
Trial: NCT05387798
Drug: RAD011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Trial: NCT06225596
Drug: BT8009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive BT8009 on Days 1, 8, and 15 of every 21-day cycle.
Trial: NCT06225596
Drug: BT8009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive BT8009 on Days 1 and 8 of every 21-day cycle.
Trial: NCT06225596
Drug: BT8009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive BT8009 on days 1, 8 +/- 15 schedule of every 21-day cycle.
Trial: NCT05355077
Drug: JT001 200mg Bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT001 (VV116):200 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Trial: NCT05355077
Drug: JT001 400mg Bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT001 (VV116):400 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Trial: NCT05355077
Drug: JT001 600mg Bid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JT001 (VV116):600 mg,oral,Twice a day,6 consecutive days and the last administration will be given in the morning on Day 6
Trial: NCT05599347
Drug: Azithromycin Pill
RxNorm normalized name: azithromycin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet - 500 mg azithromycin (as dihydrate)
Trial: NCT05891769
Drug: 18Fluorocholine
RxNorm normalized name: fluorocholine (18F)
DrugBank: Fluorocholine F-18 (DB15887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F Fluorocholine 5 mCi ± 20% administered intravenously.
Trial: NCT05496465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single treatment of placebo nasal spray
Trial: NCT05434104
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women with bacterial vaginosis will be given oral metronidazole and women with vaginal candida will be given oral fluconazole
Trial: NCT06045000
Drug: [14C]-DC-806
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT04739592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once per week for one year
Trial: NCT06451666
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle, one drop in each eye, once daily, for up to 30 days.
Trial: NCT06439082
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Trial: NCT05802303
Drug: 17-beta Estradiol gel 0.06% w/w(ESTOGEL.Intas pharma)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the Estradiol gel group patients will be administered transdermal Estradiol gel (17-beta Estradiol gel 0.06% w/w) 2 puffs thrice a day (each application contains 1.25 mg with 0.75 mg of the drug).
Trial: NCT05802303
Drug: Estradiol Hemihydrate(Estrabet Tablet, abbott pharma)
RxNorm normalized name: estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the oral Estradiol group, all women will be given 2 mg of Estradiol valerate tablets, one tablets thrice a day within 30 days of injection triptorelin depot. Endometrial assessment will be performed on D10 of HRT. Please see the flow diagram (in the annexure) for details.
Trial: NCT06199427
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
Trial: NCT05743777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle 1: 5 g (10 capsules) on days -7 and -6 and 1.5 g (3 capsules) on day -5 and every day thereafter Cycle 2 onwards: 1.5 g (3 capsules) daily
Trial: NCT04728698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent volume of placebo will be administered
Trial: NCT06238219
Drug: Neuromuscular Blocking Agent
RxNorm normalized name: Neuromuscular blocking agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of any neuromuscular blocking agent for surgery under general anesthesia
Trial: NCT05485480
Drug: conventional opioid-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the conventional opioid-based group will receive the following drugs: Remifentanil and Fentanyl
Trial: NCT05485480
Drug: opioid-sparing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to propofol as a hypnotic and rocuronium as a muscle relaxant, patients in the opioid-sparing group will receive Ketamine, Fentanyl, Lidocaine, Magnesium, Clonidine, Remifentanil
Trial: NCT00203697
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04847583
Drug: COVID-19 Standard of care
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Standard of Care treatment and administration thereof will be determined by the Investigator
Trial: NCT06500429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Including placebo
Trial: NCT00001013
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04835064
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaliplatin 85 mg/m2 intravenous infusion for 2 h, Day 1;LV 400 mg/m2 intravenous infusion for 2 h, Day 1;Irinotecan 150 mg/m2 was added 30 min after intravenous infusion for 90 min, day 1;This was immediately followed by a continuous intravenous infusion of 5-FU 2400 mg/m2 for 46 h.Repeat every 2 weeks.
Trial: NCT04062721
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (at the investigator's choice) for ≥ 2 months before RFA (with controlled disease) and resumed 4-6 weeks after RFA to achieve 6-month total duration.
Trial: NCT00281723
Drug: Pro-Pe adhesive tablet
RxNorm normalized name: ADHESIVE,PROS-AIDE II
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06110598
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is an oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in vivo. Both normal and tumor cells metabolize 5-FU to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites cause cell injury by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, bind to thymidylate synthase (TS) to form a covalently bound ternary complex. This binding inhibits the formation of thymidylate from 2'-deoxyuridylate. Thymidylate is the necessary precursor of thymidine triphosphate, which is essential for the synthesis of DNA, so that a deficiency of this compound can inhibit cell division. Second, nuclear transcriptional enzymes can mistakenly incorporate FUTP in place of uridine triphosphate (UTP) during the synthesis of RNA. This metabolic error can interfere with RNA processing and protein synthesis.
Trial: NCT05298683
Drug: Acetaminophen (paracetamol)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Route of administration: PO. Dose regimen: Acetaminophen (paracetamol) will be given at 650-1000 mg PO 15-30 minutes (but no longer than 60 minutes) before isatuximab infusion
Trial: NCT06613178
Drug: acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive IV acetaminophen (and oral placebo) or placebo IV acetaminophen and oral acetaminophen. All drugs are blinded
Trial: NCT02992756
Drug: Growth Factors
RxNorm normalized name: INVEST HEMATOLOGIC DEFICIENCIES,HEMATOPOEITIC GROWTH FACTORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose 3-6 mL of PRP obtained by PRGF Endoret
Trial: NCT04536675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative inhaler therapy with placebo once daily using Ellipta device from at least for 2 weeks preoperatively to at least 16 weeks post operatively.
Trial: NCT05183347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06326086
Drug: Targeted Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted agents as prescribed by primary treating physician
Trial: NCT06326086
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy as prescribed by primary treating physician
Trial: NCT04921969
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle cream will be applied topically twice a day for up to 8 weeks.
Trial: NCT05654064
Drug: Remifentanil-dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare adequacy of remifentanil-dexmedetomidine sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Trial: NCT05654064
Drug: Dexmedetomidine-fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare adequacy of dexmedetomidine-fentanyl sedation protocols in pregnant patients undergoing minimally invasive fetoscopic procedures.
Trial: NCT05463497
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JW0201: single administration, Tablet, Oral, BID for 5 days
Trial: NCT05463497
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2103: single administration, Tablet, Oral, BID for 5 days
Trial: NCT04676724
Drug: PegIFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be administered PegIFN.
Trial: NCT05225389
Drug: 300 mg [C14] CT1812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 300 mg CT1812 with microtracer dose of \[C14\]
Trial: NCT05038449
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy for COVID-19 according to the Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial 8th Edition)
Trial: NCT00063804
Drug: AMD070
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06319729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06613152
Drug: HS-IT201 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adoptive transfer of 5x10\^9-4x10\^10 autologous TIL to patients i.v. in 30-60 minutes.
Trial: NCT05102071
Drug: sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulfonylurea
Trial: NCT06165237
Drug: BR6001-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT06165237
Drug: BR6001-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet administered alone, Once a day
Trial: NCT05684289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06218771
Drug: TQB3454 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3454 Tablets is a selective isocitrate dehydrogenase 1 (IDH1) mutation inhibitor
Trial: NCT06223308
Drug: HB0028
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).
Trial: NCT06002659
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pre-conditioning chemotherapy
Trial: NCT00037063
Drug: Thiamine hydrochloride
RxNorm normalized name: Thiamine Hydrochloride
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00037063
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04928144
Drug: SHJ - Mid concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic
Trial: NCT05460858
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT06360965
Drug: Improved warm meridians and relieve pain plaster
RxNorm normalized name: SOMBRA Warm Pain Relieving Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from the 1st to 3rd day after the menstrual cycle is clean, apply it 6-8 hours before bedtime every day, with one day off. Apply 10 times per menstrual cycle as one course of treatment, with two consecutive courses of treatment.
Trial: NCT06360965
Drug: Traditional warm meridians and relieve pain plaster
RxNorm normalized name: SOMBRA Warm Pain Relieving Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment course is the same as the improved warm meridians and relieve pain plaster group.
Trial: NCT04260256
Drug: [18F]F-AraG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]F AraG injection and PET Scan Two tumor biopsies of single lesion
Trial: NCT06358118
Drug: Buyuan Zhixiao Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buyuan Zhixiao Formula
Trial: NCT06358118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo contains 10% of the active ingredients of the Chinese medicine group
Trial: NCT04369547
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule matched to roflumilast capsule
Trial: NCT05109117
Drug: CAP Unscented
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sunscreen lip balm.
Trial: NCT04408664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 0.9% packed in ampulla of 2 mL; Daily dosis of 4 ampulla delivered by aerosol.
Trial: NCT00095342
Drug: TMI-005
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06452602
Drug: Induction immunochemotherapy followed by concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction immunochemotherapy:~Nab-paclitaxel：220mg/m2，IV，d1，d22; Carboplatin：AUC=5，IV，d1，d22; Adebrelimab：1200mg, IV，d1, d22.~Evaluation of the Curative Effect：SD+PD~Concurrent chemoradiotherapy:~Oxaliplatin：85 mg/m2，IV，d1，d15，d29; Leucovorin：400mg/m2，IV，d1，d15，d29; 5-FU：400mg/m2，IV，d1，d15，d29; 5-FU：1600mg/m2，CIV48h，d1，d15，d29; Radiotherapy：PTV/PGTV:50.4Gy/59.92Gy/28f.
Trial: NCT01351090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal
Trial: NCT05679453
Drug: Lornoxicam 8 Mg Oral Tablet
RxNorm normalized name: lornoxicam 8 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam is a oxicam grup non-steroid antiinflamatuar drug
Trial: NCT06101147
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: These patients will receive placebo and the Metformin as prescribed by the physician for the same periods of study group
Trial: NCT05642104
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all procedures is in accordance with international guidelines and domestic expert consensus on breast cancer.
Trial: NCT05141071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of saline will be administrated enterally
Trial: NCT05429671
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Total knee arthroplasty using Stryker Surgical Simplex P with tobramycin
Trial: NCT05429671
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total knee arthroplasty using Huraeus Palacos R+G cement containing gentamicin
Trial: NCT05547256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT06184009
Drug: ALL, High risk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Description :~* Clinical and genetic factors consistent with High risk : Induction → Consolidation~  1. BM MRD \&lt; 0.01% after both Induction and Consolidation : IM #1 → DI #1 → IM #2 → Maintenance~ 2. BM MRD ≥ 0.01% after Induction, \&lt; 0.01% after Consolidation : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance~ 3. BM MRD ≥ 0.01% after Consolidation~  <!-- -->~  1. T cell ALL : Change to very high risk regimen~ 2. Pre-B ALL : IM #1 → Intensification~     1. BM MRD \&lt; 0.01% after IM #1 : Continue with \&#39;No. 2\&#39; of High risk regimen starting with DI #1~    2. BM MRD ≥ 0.01% after IM #1 : Change to Very high risk regimen~        * T cell ALL patients with M1 BM post-Consolidation will start IM #1. However, the patients will switch to Very high risk regimen at the next chemotherapy cycle once post-Consolidation MRD ≥ 0.01% has been reported.
Trial: NCT05076877
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin (breast cancer resistant protein \[BCRP\] substrate) tablet will be administered orally as a part of probe substrates.
Trial: NCT05655689
Drug: Gentamicin 1.4% + vancomycin 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the observational study, patients treated with the topical fortified antibiotics gentamicin 1.4% and vancomycin 5% eye drops as part of routine medical care are observed. The investigator does not assign any specific intervention to the study participants.
Trial: NCT05497297
Drug: HSK7653 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSK7653, tablet, oral
Trial: NCT05593653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken at bedtime for 4 weeks
Trial: NCT06136455
Drug: Listerine Total Care Zero Alcohol Mouthwash
RxNorm normalized name: Listerine Total Care Zero Alcohol Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After brushing for 1 timed minute, participants will rinse full strength for 1 minute with Listerine Total Care Zero mouthwash.
Trial: NCT06765317
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 iv D1
Trial: NCT06765317
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 iv D1
Trial: NCT06458907
Drug: Optimal medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy
Trial: NCT05118620
Drug: Placebo normal saline PENG block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A PENG block with normal saline and epinephrine will be administered using ultrasound-guidance
Trial: NCT05377112
Drug: SYNB8802v1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB8802v1 is an orally administered, non-systemically absorbed live biotherapeutic developed for the treatment of EH. The strain converts oxalate to formate and CO2, two naturally occurring GI metabolites.~SYNB8802 was developed by engineering a pathway for oxalate degradation in a probiotic strain of Escherichia coli Nissle 1917 (EcN). It is intended to act within the GI tract to reduce the oxalate levels in patients with EH by converting oxalate to formate and CO2, two naturally occurring GI metabolites.
Trial: NCT04547140
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT04547140
Drug: Standard Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMT
Trial: NCT04655508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For children between 6 to 11 years (\< 12 years): placebo of SERETIDE® 50/25 :two puffs twice a day from randomisation during 6 months using inhalation chamber For children between 12 to 17 years (\> or = 12 years) : placebo of SERETIDE® 125/25: two puffs twice a day from randomisation during 6 months using inhalation chamber
Trial: NCT04531748
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be instructed to take the pills orally around the same time in the morning and 30 minutes prior to bedtime in the evening.
Trial: NCT06470451
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Trial: NCT04322669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized in ratio of 1:1 to receive placebo matched to Pidotimod, once daily (no infection present) or twice daily (infection present) orally up to Day 60 during the double-blind treatment period.
Trial: NCT05449444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo